Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Clinical Trials Arena on MSN5d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet – Phase 1 Data Indicate Potential for Use of Once ...
News-Medical.Net on MSN5d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback